Glucagon
- Generic Name
- Glucagon
- Brand Names
- Baqsimi, Glucagen, Gvoke, Ogluo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 16941-32-5
- Unique Ingredient Identifier
- 76LA80IG2G
- Background
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.
...
- Indication
Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.
- Associated Conditions
- Severe Hypoglycemia
- Associated Therapies
- -
In Vivo Assessment of Cellular Metabolism in Humans
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- K. Sreekumaran Nair
- Target Recruit Count
- 17
- Registration Number
- NCT02748369
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation
- Conditions
- Interventions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- Institut de Recherches Cliniques de Montreal
- Target Recruit Count
- 10
- Registration Number
- NCT02626936
- Locations
- 🇨🇦
Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT02516150
- Locations
- 🇺🇸
Massachusetts General Hospital Diabetes Research Center, Boston, Massachusetts, United States
Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes
- Conditions
- Interventions
- Other: 6-day intervention with single-hormone closed-loop strategyOther: 6-day intervention with dual-hormone closed-loop strategyOther: 6-day intervention with sensor-augmented pump therapyDrug: InsulinDevice: Continuous Glucose Monitoring System Enlite sensor®, MedtronicDrug: GlucagonDevice: Insulin pump MiniMed® Paradigm® Veo™, Medtronic
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Institut de Recherches Cliniques de Montreal
- Registration Number
- NCT02490098
- Locations
- 🇨🇦
Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada
G-Pen™ for Hypoglycemia Rescue in T1D Patients
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- Xeris Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT02423980
- Locations
- 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2016-01-22
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 111
- Registration Number
- NCT02367053
- Locations
- 🇩🇪
Profil GmbH, Neuss, Germany
Effects of Glucagon Administration on Energy Expenditure
- Conditions
- Interventions
- First Posted Date
- 2014-09-11
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- AdventHealth Translational Research Institute
- Target Recruit Count
- 6
- Registration Number
- NCT02237053
- Locations
- 🇺🇸
Florida Hospital Translational Research Institute for Metabolism and Diabetes, Orlando, Florida, United States
Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT02232971
- Locations
- 🇩🇰
Hvidovre University Hospital, Hvidovre, Denmark
Glucagon Use in Colonoscopies
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 100
- Registration Number
- NCT02078726
- Locations
- 🇺🇸
San Francisco General Hospital, San Francisco, California, United States
Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Legacy Health System
- Target Recruit Count
- 12
- Registration Number
- NCT01986231
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.